在胰腺癌中对KRas4B/PDE6分子复合物的抗体的协同作用
Paola Briseño-Díaz1, Michael Schnoor1, Martiniano Bello-Ramirez2
1Department of Molecular Biomedicine, Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV-IPN), México City, Mexico.
Life science alliance
|October 9, 2023
概括
新的化合物C14和P8在胰腺癌治疗中表现有前途. 这些分子向KRas突变,减少瘤生长,并为胰腺管腺癌 (PDAC) 提供潜在的优质治疗,副作用较少.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 胰腺管道腺癌 (PDAC) 是一种致命的癌症,预后不佳,抗化疗能力高.
- K-Ras突变是PDAC发展和进展的关键驱动因素.
- 针对KRas4B/PDE6δ复合体稳定是PDAC的潜在治疗策略.
研究的目的:
- 识别和评估稳定KRas4B/PDE6δ复合物的小分子,用于PDAC治疗.
- 在临床前PDAC模型中评估新型化合物C14和P8的疗效和安全性.
主要方法:
- 在子选中识别潜在的小分子.
- 在体外测试C14和P8化合物的初级PDAC细胞和细胞系.
- 在体内研究使用患者衍生的异种移植和小鼠PDAC模型.
- 下游信号通路 (AKT,ERK) 和亡诱导的分析.
主要成果:
- 已确定并证明C14和P8化合物可以降低PDAC细胞中的K-Ras激活.
- 在患者衍生的异种移植中,C14和P8显著抑制了瘤生长.
- 结合C14和P8治疗在临床前模型中表现出协同性细胞毒性和优异的抗瘤作用,与传统疗法相比,没有观察到副作用.
- 该机制涉及AKT和ERK信号的抑制,导致特别在PDAC细胞中的亡.
结论:
- 与C14和P8的联合治疗代表了一种有希望的,可能优越的药物策略,用于改善胰腺管道腺癌的结果.
- 这些化合物通过抑制K-RAS下游信号通路提供了有针对性的方法,导致特定的PDAC细胞死亡.
相关概念视频
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
01:27Combined Effects of Drugs: Synergism
4.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.0K
01:30Combined Effects of Drugs: Antagonism
8.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.6K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
176
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
176